Allakos (FRA:37Z) Total Tax Payable : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Allakos Total Tax Payable?

Allakos's Total Tax Payable for the quarter that ended in Dec. 2023 was €0.00 Mil.

Allakos Total Tax Payable Historical Data

The historical data trend for Allakos's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Total Tax Payable Chart

Allakos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

Allakos Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	-	-

Allakos Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Allakos Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Allakos's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Allakos (FRA:37Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (FRA:37Z) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

ALLK:USA 37Z:Germany

Address

825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070

Website

https://www.allakos.com

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (FRA:37Z) Headlines

No Headlines